DOP2021000083A - Métodos de tratamiento de enfermedad renal crónica con dapagliflozina - Google Patents
Métodos de tratamiento de enfermedad renal crónica con dapagliflozinaInfo
- Publication number
- DOP2021000083A DOP2021000083A DO2021000083A DO2021000083A DOP2021000083A DO P2021000083 A DOP2021000083 A DO P2021000083A DO 2021000083 A DO2021000083 A DO 2021000083A DO 2021000083 A DO2021000083 A DO 2021000083A DO P2021000083 A DOP2021000083 A DO P2021000083A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- dapagliflozin
- methods
- kidney disease
- chronic kidney
- treatment
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 3
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 2
- 229960003834 dapagliflozin Drugs 0.000 title abstract 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación se refiere a métodos de tratamiento de pacientes con enfermedad renal crónica (ERC), con y sin diabetes tipo 2, con un inhibidor de SGLT2, tal como dapagliflozina.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063057139P | 2020-07-27 | 2020-07-27 | |
US202063070869P | 2020-08-27 | 2020-08-27 | |
US202063082524P | 2020-09-24 | 2020-09-24 | |
US202063093961P | 2020-10-20 | 2020-10-20 | |
US202063119711P | 2020-12-01 | 2020-12-01 | |
US202163152445P | 2021-02-23 | 2021-02-23 | |
US202163161629P | 2021-03-16 | 2021-03-16 | |
PCT/EP2021/058727 WO2022022865A1 (en) | 2020-07-27 | 2021-04-01 | Methods of treating chronic kidney disease with dapagliflozin |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2021000083A true DOP2021000083A (es) | 2022-04-18 |
Family
ID=79551924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2021000083A DOP2021000083A (es) | 2020-07-27 | 2021-05-03 | Métodos de tratamiento de enfermedad renal crónica con dapagliflozina |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP4188389A1 (es) |
JP (1) | JP2023536009A (es) |
KR (2) | KR20220097854A (es) |
CN (3) | CN116392472A (es) |
AU (2) | AU2021202643B2 (es) |
BR (1) | BR112021008094A2 (es) |
CA (1) | CA3116533A1 (es) |
CR (1) | CR20210222A (es) |
DO (1) | DOP2021000083A (es) |
IL (2) | IL311682A (es) |
JO (1) | JOP20210087A1 (es) |
MX (1) | MX2021005191A (es) |
PE (1) | PE20231306A1 (es) |
-
2021
- 2021-04-01 BR BR112021008094A patent/BR112021008094A2/pt unknown
- 2021-04-01 CN CN202310547700.1A patent/CN116392472A/zh active Pending
- 2021-04-01 KR KR1020217013222A patent/KR20220097854A/ko not_active IP Right Cessation
- 2021-04-01 MX MX2021005191A patent/MX2021005191A/es unknown
- 2021-04-01 PE PE2021000657A patent/PE20231306A1/es unknown
- 2021-04-01 CA CA3116533A patent/CA3116533A1/en active Pending
- 2021-04-01 JP JP2021523830A patent/JP2023536009A/ja active Pending
- 2021-04-01 CN CN202210071080.4A patent/CN114209689B/zh active Active
- 2021-04-01 AU AU2021202643A patent/AU2021202643B2/en active Active
- 2021-04-01 CN CN202180001003.5A patent/CN114630682A/zh active Pending
- 2021-04-01 CR CR20210222A patent/CR20210222A/es unknown
- 2021-04-01 KR KR1020237034971A patent/KR20230149329A/ko active Search and Examination
- 2021-04-01 IL IL311682A patent/IL311682A/en unknown
- 2021-04-01 JO JOP/2021/0087A patent/JOP20210087A1/ar unknown
- 2021-04-01 EP EP21716724.6A patent/EP4188389A1/en active Pending
- 2021-04-26 IL IL282665A patent/IL282665A/en unknown
- 2021-05-03 DO DO2021000083A patent/DOP2021000083A/es unknown
-
2023
- 2023-04-24 AU AU2023202490A patent/AU2023202490A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL282665A (en) | 2021-12-01 |
KR20230149329A (ko) | 2023-10-26 |
AU2021202643A1 (en) | 2022-02-10 |
BR112021008094A2 (pt) | 2022-02-22 |
CN116392472A (zh) | 2023-07-07 |
CN114209689B (zh) | 2023-02-17 |
KR20220097854A (ko) | 2022-07-08 |
CN114209689A (zh) | 2022-03-22 |
CN114630682A (zh) | 2022-06-14 |
MX2021005191A (es) | 2022-04-18 |
AU2023202490A1 (en) | 2023-05-11 |
EP4188389A1 (en) | 2023-06-07 |
CR20210222A (es) | 2022-08-29 |
JP2023536009A (ja) | 2023-08-23 |
PE20231306A1 (es) | 2023-08-24 |
JOP20210087A1 (ar) | 2023-01-30 |
AU2021202643B2 (en) | 2023-02-02 |
CA3116533A1 (en) | 2022-01-27 |
IL311682A (en) | 2024-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
CY1116160T1 (el) | Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας | |
CL2023001351A1 (es) | Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil. | |
AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
PH12018502593A1 (en) | Combinations of linagliptin and metformin | |
EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
EA201000673A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ | |
CR11486A (es) | Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
MX2021000295A (es) | Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon. | |
RS53128B (en) | Extending the time of disease progression or survival in patients with ovarian cancers using PERTUZUMAB | |
MX2014005996A (es) | Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia. | |
EA201170425A1 (ru) | Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения | |
MX2021000847A (es) | Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077. | |
MX2021013974A (es) | Metodos, sistemas y dispositivos de seleccion de pacientes tl1a. | |
UY39156A (es) | Métodos de tratamiento de enfermedad renal crónica con dapagliflozina | |
PH12020551076A1 (en) | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease | |
BR112022003659A2 (pt) | Composições e métodos de tratamento de doenças vasculares | |
BR112022004861A2 (pt) | Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro | |
DOP2021000083A (es) | Métodos de tratamiento de enfermedad renal crónica con dapagliflozina | |
AR121738A1 (es) | Métodos de tratamiento de enfermedad renal crónica con dapagliflozina | |
EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
EA201992852A1 (ru) | Схема дозирования тезетаксела и капецитабина | |
AR073585A1 (es) | Una proteina rica en cisteina derivada de suero en pacientes que reciben quimioterapia o radioterapia para mejorar la supervivencia de dichos pacientes. uso. metodo |